Latest News and Press Releases
Want to stay updated on the latest news?
-
Strategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio’s R&D programs targeting the identification of novel therapeuticsEntered into two new first...
-
Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
-
CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
-
Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company identifying small and large molecule...
-
メリーランド州ベセスダ、東京、ニュージャージー州チェリーヒル発, Oct. 20, 2021 (GLOBE NEWSWIRE) -- 革新的な市場ソリューションの創出を通じて、競争上の優位性を達成するために人工知能を適用する、製薬業界に特化した企業であるマソリ･セラピューティックス (MASORI Therapeutics) と、中枢神経系 (「CNS」)...
-
Engagement will combine MASORI’s global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive...
-
Engagement will combine MASORI’s global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive...
-
Cherry Hill, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
-
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...
-
Strategic Highlights Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States...